CRISPR Therapeutics submits clinical trial application for CRISPR gene-edited therapy
CRISPR Therapeutics announced the submission of a Clinical Trial Application for CTX001 in β-thalassemia. CTX001 is an investigational CRISPR gene-edited autologous hematopoietic stem cell therapy for patients suffering from β-thalassemia and sickle cell disease. December 07, 2017